A PHASE 3, MULTI-CENTER, RANDOMIZED, PARALLEL, DOUBLE MASKED, PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFTERY AND EFFICACY OF 0.1 % RGN-259 OPHTHALMIC SOLUTION FOR THE TREATMENT OF NEUROTROPHIC KERATOPATHY (SEER-2),
Role: PI,
ReGen Tree, LLC,
(08/2023 - 08/2024)
Status: Approved
Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants with Persistent Corneal Epithelial Defect (PCED),
Role: PI,
Combangio, Inc.,
(05/2023 - 05/2024)
Status: Approved
CSB-C20-003: A Multi-Center. Randomized, Double-Masked, Vehicle-Controlled. Parallel-Group. Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1 % in stage 2 and 3 Neurotrophic Keratitis Subjects,
Role: PI,
Claris Biotherapeutics,
(11/2023 - 11/2024)
Status: Approved
Internal
Retrospective Analysis of Incidence, Prevalence, and Treatment Modalities of Neurotrophic Keratitis Post-Retinal Procedures,
Role: Investigator,
LLU Dept. of Ophthalmology,
(08/2023)
Status: Approved
The effects of call on dry eye symptoms as measured by the Schirmer Test,
Role: PI,
LLU Dept. of Ophthalmology,
(07/2013 - 07/2014)
Status: Completed